Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer

PurposePatients with locally advanced non-small cell lung cancer (LA-NSCLC) have a high prevalence of pre-existing coronary heart disease and face excess cardiac risk after thoracic radiation therapy. We sought to assess whether statin therapy is predictor overall survival (OS) therapy.Methods MaterialsWe performed retrospective analysis 748 patients LA-NSCLC treated therapy, using Kaplan-Meier OS estimates Cox regression.ResultsStatin use among (Framingham ?20% or disease; n = 496) was 51.2%. After adjustment for baseline other prognostic factors, associated significantly increased all-cause mortality (adjusted hazard ratio, 1.39; 95% confidence interval [CI], 1.00-1.91; P .048) but not major adverse events 1.18; CI, 0.52-2.68; .69). Among statin-naïve patients, mean dose ?10 Gy versus <10 (hazard 1.32; 1.04-1.68; .022), 2-year 46.9% 60.0%, respectively. However, did differ by on 1.00; 0.76-1.32; P-interaction .031), 50.3%, respectively.ConclusionsAmong LA-NSCLC, only half statin-eligible were reflecting the highest level our cohort. Statin an independent events. Elevated (?10 Gy) in those identifying group which early intervention statins may mitigate deleterious effects dose. This warrants evaluation prospective trials.